Absolute rubbish! You sound like the type that needs spoon...

Absolute rubbish! You sound like the type that needs spoon feeding beyond babyhood.

The lumpy, non-linear nature of clinical trials was explained in detail in the announcement as well as the actual cost and the confirmation that the trial is funded to completion.

Nina doesn't have to hold the hands of shareholders who are ignorant of the processes. In fact, it is reasonable of her to assume that anyone who invests in a company has done their DD and has a mature understanding of what the Company is about and the specifics of what it does. She should not concern herself with all the ill-informed 'gamblers' who hop on the latest thing just because there is momentum or swing trade opportunities.

Everyone should know that the strategy was to rapidly open 100+ new sites following the 1st interim and that this would be reflected in the Quarterly spend.

There's plenty of info on the web re the cost of initiating phase 3 trial sites (such as https://www.sofpromed.com/how-much-does-a-phase-3-clinical-trial-cost), so anyone who bothered to get off their arse could have identified and anticipated the ball-park costs.